Download PDF
Journal of Pediatric Neurology 2017; 15(06): 316-324
DOI: 10.1055/s-0037-1603349
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Phenotypic Variability and mTOR Pathway Gene Aberrations in Familial Tuberous Sclerosis

Winnie S. Liang
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Shobana Sekar
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Sara Nasser
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Jonathan Adkins
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Lori Cuyugan
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Daniel Enriquez
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Sampath Rangasamy
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
,
Vinodh Narayanan
1   Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, United States
› Author Affiliations
Further Information

Publication History

03 January 2017

16 April 2017

Publication Date:
22 May 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that demonstrates variable severity, such that affected family members may have mild or severe disease. We performed exome and RNA sequencing of blood leukocytes from mild and severe cases across four families to identify mTOR pathway aberrations that may underlie phenotypic variability. In each family, we identified TSC1/TSC2 aberrations along with different mTOR pathway gene alterations, including base substitutions, deletions, and skewed allelic frequencies. Here, we describe the first reported DNA and RNA analysis of TSC families demonstrating mTOR pathway aberrations in mild and severe forms of the disease.

Keywords

familial tuberous sclerosis - phenotypic variability - next generation sequencing

Supplementary Material

 

  • References

  • 1 European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75 (07) 1305-1315
    CrossrefPubMedGoogle Scholar
  • 2 Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000; 107 (02) 97-114
    CrossrefPubMedGoogle Scholar
  • 3 van Slegtenhorst M, de Hoogt R, Hermans C. , et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277 (5327): 805-808
    CrossrefPubMedGoogle Scholar
  • 4 Crino PB. The pathophysiology of tuberous sclerosis complex. Epilepsia 2010; 51 (Suppl. 01) 27-29
    PubMedGoogle Scholar
  • 5 Northrup H, Wheless JW, Bertin TK, Lewis RA. Variability of expression in tuberous sclerosis. J Med Genet 1993; 30 (01) 41-43
    CrossrefPubMedGoogle Scholar
  • 6 Rok P, Kasprzyk-Obara J, Domańska-Pakieła D, Jóźwiak S. Clinical symptoms of tuberous sclerosis complex in patients with an identical TSC2 mutation. Med Sci Monit 2005; 11 (05) CR230-CR234
    PubMedGoogle Scholar
  • 7 Jones AC, Shyamsundar MM, Thomas MW. , et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64 (05) 1305-1315
    CrossrefPubMedGoogle Scholar
  • 8 Sancak O, Nellist M, Goedbloed M. , et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 2005; 13 (06) 731-741
    CrossrefPubMedGoogle Scholar
  • 9 van Slegtenhorst M, Verhoef S, Tempelaars A. , et al. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J Med Genet 1999; 36 (04) 285-289
    PubMedGoogle Scholar
  • 10 Crino PB. Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol 2013; 125 (03) 317-332
    CrossrefPubMedGoogle Scholar
  • 11 de Vries PJ, Howe CJ. The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment. Trends Mol Med 2007; 13 (08) 319-326
    CrossrefPubMedGoogle Scholar
  • 12 Ehninger D, de Vries PJ, Silva AJ. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res 2009; 53 (10) 838-851
    CrossrefPubMedGoogle Scholar
  • 13 Han S, Santos TM, Puga A. , et al. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 2004; 64 (03) 812-816
    CrossrefPubMedGoogle Scholar
  • 14 Ma L, Teruya-Feldstein J, Bonner P. , et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007; 67 (15) 7106-7112
    CrossrefPubMedGoogle Scholar
  • 15 Qin W, Chan JA, Vinters HV. , et al. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol 2010; 20 (06) 1096-1105
    CrossrefPubMedGoogle Scholar
  • 16 Caban C, Khan N, Hasbani DM, Crino PB. Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet 2016; 10: 1-8
    CrossrefPubMedGoogle Scholar
  • 17 Jancic J, Duric V, Ivancevic N, Nikolic B, van den Anker JN, Samardzic J. Current Use of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas and epilepsy in patients with TSC. Curr Med Chem 2016; 23 (37) 4260-4269
    CrossrefPubMedGoogle Scholar
  • 18 Humphrey A, Ploubidis GB, Yates JR, Steinberg T, Bolton PF. The Early Childhood Epilepsy Severity Scale (E-Chess). Epilepsy Res 2008; 79 (2-3): 139-145
    CrossrefPubMedGoogle Scholar
  • 19 Speechley KN, Sang X, Levin S. , et al. Assessing severity of epilepsy in children: preliminary evidence of validity and reliability of a single-item scale. Epilepsy Behav 2008; 13 (02) 337-342
    CrossrefPubMedGoogle Scholar
  • 20 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25 (14) 1754-1760
    CrossrefPubMedGoogle Scholar
  • 21 Hoogeveen-Westerveld M, Exalto C, Maat-Kievit A, van den Ouweland A, Halley D, Nellist M. Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction. Biochim Biophys Acta 2010; 1802 (09) 774-781
    CrossrefPubMedGoogle Scholar
  • 22 Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014; 11 (04) 361-362
    CrossrefPubMedGoogle Scholar
  • 23 Shihab HA, Gough J, Cooper DN. , et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 2013; 34 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 24 Hymowitz SG, Patel DR, Wallweber HJ. , et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 2005; 280 (08) 7218-7227
    CrossrefPubMedGoogle Scholar
  • 25 Kim JS, Ro SH, Kim M. , et al. Sestrin2 inhibits mTORC1 through modulation of GATOR complexes. Sci Rep 2015; 5: 9502 . Doi: 10.1038/srep09502
    CrossrefPubMedGoogle Scholar
  • 26 Parmigiani A, Nourbakhsh A, Ding B. , et al. Sestrins inhibit mTORC1 kinase activation through the GATOR complex. Cell Reports 2014; 9 (04) 1281-1291
    CrossrefPubMedGoogle Scholar
  • 27 Dokudovskaya S, Rout MP. SEA you later alli-GATOR--a dynamic regulator of the TORC1 stress response pathway. J Cell Sci 2015; 128 (12) 2219-2228
    CrossrefPubMedGoogle Scholar
  • 28 Gan X, Wang J, Wang C. , et al. PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12. Nat Cell Biol 2012; 14 (07) 686-696
    CrossrefPubMedGoogle Scholar
  • 29 Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013; Chapter 7: 20 . Doi: 10.1002/0471142905.hg0720s76
    PubMedGoogle Scholar
  • 30 Kim DH, Sarbassov DD, Ali SM. , et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110 (02) 163-175
    CrossrefPubMedGoogle Scholar
  • 31 Chan JA, Zhang H, Roberts PS. , et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004; 63 (12) 1236-1242
    CrossrefPubMedGoogle Scholar
  • 32 Henske EP, Scheithauer BW, Short MP. , et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996; 59 (02) 400-406
    PubMedGoogle Scholar
  • 33 Tyburczy ME, Wang JA, Li S. , et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet 2014; 23 (08) 2023-2029
    CrossrefPubMedGoogle Scholar
  • 34 Jambaqué I, Cusmai R, Curatolo P, Cortesi F, Perrot C, Dulac O. Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings. Dev Med Child Neurol 1991; 33 (08) 698-705
    CrossrefPubMedGoogle Scholar
  • 35 Shepherd CW, Houser OW, Gomez MR. MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. Am J Neuroradiol 1995; 16 (01) 149-155
    PubMedGoogle Scholar
  • 36 Giannantoni NM, Restuccia D, Della Marca G, Alfano RM, Vollono C. A novel TSC2 mutation causing tuberless tuberous sclerosis. Seizure 2014; 23 (07) 580-582
    CrossrefPubMedGoogle Scholar
  • 37 Kaufmann R, Kornreich L, Goldberg-Stern H. Unusual clinical presentation of tuberless tuberous sclerosis complex. J Child Neurol 2009; 24 (03) 361-364
    CrossrefPubMedGoogle Scholar
  • 38 Joinson C, O'Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003; 33 (02) 335-344
    CrossrefPubMedGoogle Scholar
  • 39 Jones AC, Daniells CE, Snell RG. , et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 1997; 6 (12) 2155-2161
    CrossrefPubMedGoogle Scholar
  • 40 Lewis JC, Thomas HV, Murphy KC, Sampson JR. Genotype and psychological phenotype in tuberous sclerosis. J Med Genet 2004; 41 (03) 203-207
    CrossrefPubMedGoogle Scholar
  • 41 Jansen AC, Sancak O, D'Agostino MD. , et al. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol 2006; 60 (05) 528-539
    CrossrefPubMedGoogle Scholar
  • 42 Lyczkowski DA, Conant KD, Pulsifer MB. , et al. Intrafamilial phenotypic variability in tuberous sclerosis complex. J Child Neurol 2007; 22 (12) 1348-1355
    CrossrefPubMedGoogle Scholar
  • 43 Smalley SL, Burger F, Smith M. Phenotypic variation of tuberous sclerosis in a single extended kindred. J Med Genet 1994; 31 (10) 761-765
    CrossrefPubMedGoogle Scholar
  • 44 Au KS, Ward CH, Northrup H. Tuberous sclerosis complex: disease modifiers and treatments. Curr Opin Pediatr 2008; 20 (06) 628-633
    CrossrefPubMedGoogle Scholar
  • 45 Humphrey A, Higgins JN, Yates JR, Bolton PF. Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits. Neurology 2004; 62 (05) 795-798
    CrossrefPubMedGoogle Scholar
  • 46 Kwiatkowska J, Wigowska-Sowinska J, Napierala D, Slomski R, Kwiatkowski DJ. Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. N Engl J Med 1999; 340 (09) 703-707
    CrossrefPubMedGoogle Scholar
  • 47 Kwiatkowski D. TSC1, TSC2, TSC3? Or mosaicism?. Eur J Hum Genet 2005; 13 (06) 695-696
    CrossrefPubMedGoogle Scholar
  • 48 Jentarra GM, Rice SG, Olfers S, Saffen D, Narayanan V. Evidence for population variation in TSC1 and TSC2 gene expression. BMC Med Genet 2011; 12: 29 . Doi: 10.1186/1471-2350-12-29
    PubMedGoogle Scholar
  • 49 Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet 2013; 14: 355-369
    CrossrefPubMedGoogle Scholar